Form 4: RA Capital Reduces Stake in Werewolf Therapeutics

RA Capital Management has disclosed the sale of approximately 448,850 shares of Werewolf Therapeutics (HOWL) across three trading days in June 2026.

Summary

• RA Capital Management, L.P. and associated entities sold a total of 448,850 shares of Werewolf Therapeutics (HOWL) between June 12 and June 16, 2026.
• The sales were executed at weighted average prices ranging from $0.37 to $0.40 per share.
• Following these transactions, the reporting persons maintain a significant beneficial ownership stake in the company.
• The transactions were conducted by RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as bearish sentiment, as significant selling by a major institutional shareholder often creates downward pressure on the stock price.

Positives

• The reporting entities remain substantial shareholders, indicating continued, albeit reduced, investment interest.

Negatives

• The divestment of nearly 450,000 shares by a major institutional investor may signal a lack of confidence in the near-term stock performance.
• The shares were sold at prices below $0.50, reflecting a low valuation for the equity.

Risks

• Continued selling pressure from a 10% owner could negatively impact the share price.
• The low trading price of the stock may pose challenges for capital raising or maintaining exchange listing requirements.

Future Outlook

No specific forward-looking guidance was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotech firms often reflects portfolio rebalancing or a shift in risk appetite regarding clinical-stage development timelines.

Comparison to Industry Standards

• The sale of shares by a 10% owner is a standard regulatory disclosure and does not necessarily reflect a change in the company's fundamental clinical progress.
• The price point of under $0.50 is consistent with the volatility often seen in micro-cap biotechnology equities.

Stakeholder Impact

• Shareholders may experience increased volatility due to the institutional sell-off.
• The reduction in stake by a major investor may influence market perception of the company's valuation.

Next Steps

• Monitor future SEC filings for further changes in beneficial ownership by RA Capital Management.

Key Dates

Recommendation

Investors should hold until further clarity is provided on the company's clinical pipeline and cash runway, as the institutional selling suggests a lack of immediate upside conviction.

Keywords

Werewolf Therapeutics, HOWL, RA Capital Management, Insider Selling, Biotech, SEC Form 4